Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917266 | 0.85 | RXFP1 (0.44) | KMT2AMEN1LMNARXFP1ALDH1A1 | |
| SCHEMBL24760246 | 0.84 | KMT2A (0.38) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL12452413 | 0.83 | RXFP1 (0.41) | KMT2AMEN1LMNARXFP1ALDH1A1 | |
| SCHEMBL11946728 | 0.82 | ALDH1A1 (0.55) | KMT2AMEN1LMNARXFP1ALDH1A1 | |
| SCHEMBL21861995 | 0.82 | CTSB (0.37) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL2742150 | 0.82 | MEN1 (0.52) | KMT2AMEN1LMNAALDH1A1TDP1 | |
| SCHEMBL20420548 | 0.81 | RXFP1 (0.42) | KMT2AMEN1LMNARXFP1ALDH1A1 | |
| SCHEMBL26210056 | 0.80 | POLB (0.46) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL12116549 | 0.80 | ALDH1A1 (0.45) | KMT2AALDH1A1MAPTCA1CA2 | |
| SCHEMBL22388944 | 0.80 | LMNA (0.45) | KMT2AMEN1LMNARXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162323-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | BICYCLETX LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162323-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | FGFR2, FGFR3, FGFR1 | KMT2A 1825/4885MEN1 3646/4885LMNA 4657/4885 |
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | TP53, VHL, MYC | KMT2A 619/4885MEN1 900/4885LMNA 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.